GEMIN4 functions as a coregulator of the mineralocorticoid receptor

Journal of Molecular Endocrinology

Volumn 54, Issue 2, 2015, Pages 149-160

  Yang, Jun ^a,b   Fuller, Peter J ^a,b   Morgan, James ^a   Shibata, Hirotaka ^c   Clyne, Colin D ^a   Young, Morag J ^a,b  

^a HUDSON INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c OITA UNIVERSITY   (Japan)

Author keywords

Coactivator; Corepressor; GEMIN4; Mineralocorticoid receptor(MR)

Indexed keywords

CELL NUCLEUS RECEPTOR; GEMIN4 PROTEIN; MESSENGER RNA; MINERALOCORTICOID RECEPTOR; MPXLXXLL PROTEIN; REGULATOR PROTEIN; UNCLASSIFIED DRUG; ALDOSTERONE; GEMIN4 PROTEIN, HUMAN; GEMIN4 PROTEIN, RAT; NUCLEAR PROTEIN; REPRESSOR PROTEIN; SMALL NUCLEAR RIBONUCLEOPROTEIN;

ANIMAL CELL; ARTICLE; CELL GROWTH; CELL LINE; CELL SPECIFICITY; CONSENSUS SEQUENCE; CONTROLLED STUDY; GENE OVEREXPRESSION; GENE TARGETING; HEART PROTECTION; HEK293 CELL LINE; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN DATABASE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN MOTIF; PROTEIN PROTEIN INTERACTION; SEQUENCE ALIGNMENT; TRANSACTIVATION; TRANSIENT TRANSFECTION; AMINO ACID SEQUENCE; ANIMAL; CELL NUCLEUS; CHEMISTRY; DRUG EFFECTS; GENE SILENCING; METABOLISM; MOLECULAR GENETICS; PROTEIN TRANSPORT; RAT; TRANSCRIPTION INITIATION;

ALDOSTERONE; AMINO ACID MOTIFS; AMINO ACID SEQUENCE; ANIMALS; CELL NUCLEUS; CONSENSUS SEQUENCE; DATABASES, PROTEIN; GENE KNOCKDOWN TECHNIQUES; HEK293 CELLS; HUMANS; MOLECULAR SEQUENCE DATA; NUCLEAR PROTEINS; PROTEIN TRANSPORT; RATS; RECEPTORS, MINERALOCORTICOID; REPRESSOR PROTEINS; RIBONUCLEOPROTEINS, SMALL NUCLEAR; SEQUENCE ALIGNMENT; TRANSCRIPTIONAL ACTIVATION;

EID: 84929091720     PISSN: 09525041     EISSN: 14796813     Source Type: Journal    
DOI: 10.1530/JME-14-0078     Document Type: Article

References (69)

1. Arriza JL, Weinberger C, Cerelli G, Glaser TM, Handelin BL, Housman DE & Evans RM 1987 Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. Science v237 268. (doi:10.1126/science.3037703)
2. Bramlett KS, Wu Y & Burris TP 2001 Ligands specify coactivator nuclear receptor (NR) box affinity for estrogen receptor subtypes. Molecular Endocrinology 15 909–922. (doi:10.1210/mend.15.6.0649)
3. Caprio M, Feve B, Claes A, Viengchareun S, Lombes M & Zennaro M-C 2007 Pivotal role of themineralocorticoid receptor in corticosteroid-induced adipogenesis. FASEB Journal 21 2185–2194. (doi:10.1096/fj.06-7970com)
4. Cato ACB & Fuller PJ 2012 What is in a name? Molecular and Cellular Endocrinology 350 145. (doi:10.1016/j.mce.2011.08.011)
5. Chang C & McDonnell DP 2005 Androgen receptor-cofactor interactions as targets for new drug discovery. Trends in Pharmacological Sciences 26 225–228. (doi:10.1016/j.tips.2005.03.002)
6. Chang C-y, Norris JD, Jansen M, Huang H-J & McDonnell DP 2003 Application of random peptide phage display to the study of nuclear hormone receptors. Methods in Enzymology 364 118–142.
7. Chang Cy, Norris JD, Gron H, Paige LA, Hamilton PT, Kenan DJ, Fowlkes D & McDonnell DP 1999 Dissection of the LXXLL nuclear receptor– coactivator interaction motif using combinatorial peptide libraries: discovery of peptide antagonists of estrogen receptors a and b. Molecular and Cellular Biology 19 8226–8239.
8. Charroux B, Pellizzoni L, Perkinson RA, Yong J, Shevchenko A, Mann M & Dreyfuss G 2000 Gemin4. A novel component of the SMNcomplex that is found in both gems and nucleoli. Journal of Cell Biology 148 1177–1186. (doi:10.1083/jcb.148.6.1177)
9. Clyne CD, Chang C-Y, Safi R, Fuller PJ, McDonnell DP & Young MJ 2009 Purification and characterization of recombinant human mineralocorticoid receptor. Molecular and Cellular Endocrinology 302 81–85. (doi:10.1016/j.mce.2008.11.030)
10. Dong X, Sweet J, Challis JR, Brown T & Lye SJ 2007 Transcriptional activity of androgen receptor is modulated by two RNA splicing factors, PSF and p54nrb. Molecular and Cellular Biology 27 4863–4875. (doi:10.1128/MCB.02144-06)
11. Galigniana MD 1996 Stability study on renal type I mineralocorticoid receptor. Life Sciences 59 511–521. (doi:10.1016/0024-3205(96)00331-1)
12. Gall JG 2003 The centennial of the Cajal body. Nature Reviews. Molecular Cell Biology 4 975–980. (doi:10.1038/nrm1262)
13. Gomez-Sanchez CE, Warden M, Gomez-Sanchez MT, Hou X & Gomez-Sanchez EP 2011 Diverse immunostaining patterns of mineralocorticoid receptor monoclonal antibodies. Steroids 76 1541–1545. (doi:10.1016/j.steroids.2011.09.004)
14. Griekspoor A, Zwart W, Neefjes J & Michalides R 2007 Visualizing the action of steroid hormone receptors in living cells. Nuclear Receptor Signaling 5 e003.
15. Group EBCTC 1998 Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists’ Collaborative Group. Lancet 351 1451–1467. (doi:10.1016/S0140-6736(97)11423-4)
16. Hall JM, Chang CY & McDonnell DP 2000 Development of peptide antagonists that target estrogen receptor beta-coactivator interactions. Molecular Endocrinology 14 2010–2023.
17. Heemers HV & Tindall DJ 2007 Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex. Endocrine Reviews 28 778–808. (doi:10.1210/er.2007-0019)
18. Jaber B, Mukopadhyay R & Smith C 2004 Estrogen receptor-a interaction with the CREB binding protein coactivator is regulated by the cellular environment. Journal of Molecular Endocrinology 32 307–323. (doi:10.1677/jme.0.0320307)
19. Jagannathan V & Robinson-Rechavi M 2011 The challenge of modeling nuclear receptor regulatory networks in mammalian cells. Molecular and Cellular Endocrinology 334 91–97. (doi:10.1016/j.mce.2010.06.012)
20. Jordan VC 1992 The strategic use of antiestrogens to control the development and growth of breast cancer. Cancer 70 977–982.
21. Klinge CM, Jernigan SC, Mattingly KA, Risinger KE & Zhang J 2004 Estrogen response element-dependent regulation of transcriptional activation of estrogen receptors a and b by coactivators and corepressors. Journal of Molecular Endocrinology 33 387–410. (doi:10.1677/jme.1.01541)
22. Klokk TI, Kurys P, Elbi C, Nagaich AK, Hendarwanto A, Slagsvold T, Chang CY, Hager GL & Saatcioglu F 2007 Ligand-specific dynamics of the androgen receptor at its response element in living cells. Molecular and Cellular Biology 27 1823–1843. (doi:10.1128/MCB.01297-06)
23. Kodera Y, Takeyama K, Murayama A, Suzawa M, Masuhiro Y & Kato S 2000 Ligand type-specific interactions of peroxisome proliferator-activated receptor g with transcriptional coactivators. Journal of Biological Chemistry 275 33201–33204. (doi:10.1074/jbc.C000517200)
24. Kraichely DM, Sun J, Katzenellenbogen JA & Katzenellenbogen BS 2000 Conformational changes and coactivator recruitment by novel ligands for estrogen receptor-a and estrogen receptor-b: correlations with biological character and distinct differences among SRC coactivator family members. Endocrinology 141 3534–3545.
25. Kurihara I, Shibata H, Kobayashi S, Suda N, Ikeda Y, Yokota K, Murai A, Saito I, Rainey WE & Saruta T 2005 Ubc9 and protein inhibitor of activated STAT 1 activate chicken ovalbumin upstream promotertranscription factor I-mediated human CYP11B2 gene transcription. Journal of Biological Chemistry 280 6721–6730. (doi:10.1074/jbc.M411820200)
26. Lalevé N, Rebsamen MC, Barrère-Lemaire S, Perrier E, Nargeot J, Bénitah J-P & Rossier MF 2005 Aldosterone increases T-type calcium channel expression and in vitro beating frequency in neonatal rat cardiomyocytes. Cardiovascular Research 67 216–224.
27. Li X, Wong J, Tsai SY, Tsai M-J & O’Malley BW 2003 Progesterone and glucocorticoid receptors recruit distinct coactivator complexes and promote distinct patterns of local chromatin modification. Molecular and Cellular Biology 23 3763–3773. (doi:10.1128/MCB.23.11.3763-3773.2003)
28. Lombes M, Oblin ME, Gasc JM, Baulieu EE, Farman N & Bonvalet JP 1992 Immunohistochemical and biochemical evidence for a cardiovascular mineralocorticoid receptor. Circulation Research 71 503–510. (doi:10.1161/01.RES.71.3.503)
29. Lombes M, Farman N, Bonvalet JP & Zennaro MC 2000 Identification and role of aldosterone receptors in the cardiovascular system. Annales d’Endocrinologie 61 41–46.
30. Lonard DM & O’Malley BW 2006 The expanding cosmos of nuclear receptor coactivators. Cell 125 411–414.
31. Lorson MA, Dickson AM, Shaw DJ, Todd AG, Young EC, Morse R, Wolstencroft C, Lorson CL & Young PJ 2008 Identification and characterisation of a nuclear localisation signal in the SMN associated protein, Gemin4. Biochemical and Biophysical Research Communications 375 33–37. (doi:10.1016/j.bbrc.2008.07.113)
32. Lu NZ, Wardell SE, Burnstein KL, Defranco D, Fuller PJ, Giguere V, Hochberg RB, McKay L, Renoir JM, Weigel NL et al. 2006 International Union of Pharmacology. LXV. The pharmacology and classification of the nuclear receptor superfamily: glucocorticoid, mineralocorticoid, progesterone, and androgen receptors. Pharmacological Reviews 58 782–797. (doi:10.1124/pr.58.4.9)
33. McKenna NJ & O’Malley BW 2000 From ligand to response: generating diversity in nuclear receptor coregulator function. The Journal of Steroid Biochemistry and Molecular Biology 74 351–356.
34. Malovannaya A, Lanz Rainer B, Jung Sung Y, Bulynko Y, Le Nguyen T, Chan Doug W, Ding C, Shi Y, Yucer N, Krenciute G et al. 2011 Analysis of the human endogenous coregulator complexome. Cell 145 787–799. (doi:10.1016/j.cell.2011.05.006)
35. McDonnell DP & Wardell SE 2010 The molecular mechanisms underlying the pharmacological actions of ER modulators: implications for new drug discovery in breast cancer. Current Opinion in Pharmacology 10 620–628. (doi:10.1016/j.coph.2010.09.007)
36. McKenna NJ 2011 Discovery-driven research and bioinformatics in nuclear receptor and coregulator signaling. Biochimica et Biophysica Acta 1812 808–817. (doi:10.1016/j.bbadis.2010.10.009)
37. Meijer OC 2002 Coregulator proteins and corticosteroid action in the brain. Journal of Neuroendocrinology 14 499–505. (doi:10.1046/j.1365-2826.2002.00795.x)
38. Meister G, Bühler D, Laggerbauer B, Zobawa M, Lottspeich F & Fischer U 2000 Characterization of a nuclear 20S complex containing the survival of motor neurons (SMN) protein and a specific subset of spliceosomal Sm proteins. Human Molecular Genetics 9 1977–1986. (doi:10.1093/hmg/9.13.1977)
39. Mettu NB, Stanley TB, Dwyer MA, Jansen MS, Allen JE, Hall JM & McDonnell DP 2007 The nuclear receptor–coactivator interaction surface as a target for peptide antagonists of the peroxisome proliferator-activated receptors. Molecular Endocrinology 21 2361–2377. (doi:10.1210/me.2007-0201)
40. Murai-Takeda A, Shibata H, Kurihara I, Kobayashi S, Yokota K, Suda N, Mitsuishi Y, Jo R, Kitagawa H, Kato S et al. 2010 NF-YC functions as a corepressor of agonist-bound mineralocorticoid receptor. Journal of Biological Chemistry 285 8084–8093. (doi:10.1074/jbc.M109.053371)
41. Náray-Fejes-Toóth A, Canessa C, Cleaveland ES, Aldrich G & Fejes-Tóth G 1999 sgk is an aldosterone-induced kinase in the renal collecting duct. Journal of Biological Chemistry 274 16973–16978.
42. Obradovic D, Tirard M, Nemethy Z, Hirsch O, Gronemeyer H & Almeida OF 2004 DAXX, FLASH, and FAF-1 modulate mineralocorticoid and glucocorticoid receptor-mediated transcription in hippocampal cells: toward a basis for the opposite actions elicited by two nuclear receptors? Molecular Pharmacology 65 761–769. (doi:10.1124/mol.65.3.761)
43. O’Malley BW 2003 Sequentiality and processivity of nuclear receptor coregulators in regulation of target gene expression. Nuclear Receptor Signaling 1 e010. (doi:10.1621/nrs.01010)
44. Onate SA, Tsai SY, Tsai M-J & O’Malley BW 1995 Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science v270 1354.
45. Pascual-Le Tallec L, Kirsh O, Lecomte M-C, Viengchareun S, Zennaro M-C, Dejean A & Lombes M 2003 Protein inhibitor of activated signal transducer and activator of transcription 1 interacts with the N-terminal domain of mineralocorticoid receptor and represses its transcriptional activity: implication of small ubiquitin-related modifier 1 modification. Molecular Endocrinology 17 2529–2542. (doi:10.1210/me.2003-0299)
46. Pascual-Le Tallec L, Simone F, Viengchareun S, Meduri G, Thirman MJ & Lombes M 2005 The elongation factor ELL (eleven-nineteen lysine-rich leukemia) is a selective coregulator for steroid receptor functions. Molecular Endocrinology 19 1158–1169. (doi:10.1210/me.2004-0331)
47. Pellizzoni L, Yong J & Dreyfuss G 2002 Essential role for the SMN complex in the specificity of snRNP assembly. Science 298 1775–1779. (doi:10.1126/science.1074962)
48. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J & The Randomized Aldactone Evaluation Study I 1999 The effect of spironolactone on morbidity and mortality in patients with severe heart failure. New England Journal of Medicine 341 709–717. (doi:10.1056/NEJM199909023411001)
49. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M et al. 2003 Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. New England Journal of Medicine 348 1309–1321. (doi:10.1056/NEJMoa030207)
50. Qin W, Rudolph AE, Bond BR, Rocha R, Blomme EA, Goellner JJ, Funder JW & McMahon EG 2003 Transgenic model of aldosterone-driven cardiac hypertrophy and heart failure. Circulation Research 93 69–76. (doi:10.1161/01.RES.0000080521.15238.E5)
51. Rickard AJ, Morgan J, Tesch G, Funder JW, Fuller PJ & Young MJ 2009 Deletion of mineralocorticoid receptors from macrophages protects against deoxycorticosterone/salt-induced cardiac fibrosis and increased blood pressure. Hypertension 54 537–543. (doi:10.1161/HYPERTENSIONAHA.109.131110)
52. Rogerson FM & Fuller PJ 2000 Mineralocorticoid action. Steroids 65 61–73. (doi:10.1016/S0039-128X(99)00087-2)
53. Rogerson FM, Yao Y-Z, Young MJ & Fuller PJ 2014 Identification and characterization of a ligand-selective mineralocorticoid receptor coactivator. FASEB Journal 28 4200–4210. (doi:10.1096/fj.13-242479)
54. Safi R, Kovacic A, Gaillard S, Murata Y, Simpson ER, McDonnell DP & Clyne CD 2005 Coactivation of liver receptor homologue-1 by peroxisome proliferator-activated receptor {g} coactivator-1{a} on aromatase promoter II and its inhibition by activated retinoid X receptor suggest a novel target for breast-specific antiestrogen therapy. Cancer Research 65 11762–11770. (doi:10.1158/0008-5472.CAN-05-2792)
55. Sekizawa N, Yoshimoto T, Hayakawa E, Suzuki N, Sugiyama T & Hirata Y 2011 Transcriptome analysis of aldosterone-regulated genes in human vascular endothelial cell lines stably expressing mineralocorticoid receptor. Molecular and Cellular Endocrinology 341 78–88. (doi:10.1016/j.mce.2011.05.029)
56. Smith CL & O’Malley BW 2004 Coregulator function: a key to understanding tissue specificity of selective receptor modulators. Endocrine Reviews 25 45–71. (doi:10.1210/er.2003-0023)
57. Soundararajan R, Zhang TT, Wang J, Vandewalle A & Pearce D 2005 A novel role for glucocorticoid-induced leucine zipper protein in epithelial sodium channel-mediated sodium transport. Journal of Biological Chemistry 280 39970–39981. (doi:10.1074/jbc.M508658200)
58. Sutanto W & de Kloet ER 1991 Mineralocorticoid receptor ligands: biochemical, pharmacological, and clinical aspects. Medicinal Research Reviews 11 617–639. (doi:10.1002/med.2610110604)
59. Tanaka K, Ashizawa N, Kawano H, Sato O, Seto S, Nishihara E, Terazono H, Isomoto S, Shinohara K & Yano K 2007 Aldosterone induces circadian gene expression of clock genes in H9c2 cardiomyoblasts. Heart and Vessels 22 254–260. (doi:10.1007/s00380-006-0968-3)
60. Todd AG, Morse R, Shaw DJ, Stebbings H & Young PJ 2010 Analysis of SMN–neurite granules: core Cajal body components are absent from SMN–cytoplasmic complexes. Biochemical and Biophysical Research Communications 397 479–485. (doi:10.1016/j.bbrc.2010.05.139)
61. Turner RT, Wakley GK, Hannon KS & Bell NH 1987 Tamoxifen prevents the skeletal effects of ovarian hormone deficiency in rats. Journal of Bone and Mineral Research 2 449–456. (doi:10.1002/jbmr.5650020513)
62. Won Jeong K, Chodankar R, Purcell DJ, Bittencourt D & Stallcup MR 2012 Gene-specific patterns of coregulator requirements by estrogen receptor-a in breast cancer cells. Molecular Endocrinology 26 955–966. (doi:10.1210/me.2012-1066)
63. Wood JR, Likhite VS, LovenMA & Nardulli AM 2001 Allosteric modulation of estrogen receptor conformation by different estrogen response elements. Molecular Endocrinology 15 1114–1126. (doi:10.1210/mend.15.7.0671)
64. Yang J & Young MJ 2009 The mineralocorticoid receptor and its coregulators. Journal of Molecular Endocrinology 43 53–64. (doi:10.1677/JME-09-0031)
65. Yang J, Chang CY, Safi R, Morgan J, McDonnell DP, Fuller PJ, Clyne CD & Young MJ 2011 Identification of ligand-selective peptide antagonists of the mineralocorticoid receptor using phage display. Molecular Endocrinology 25 32–43. (doi:10.1210/me.2010-0193)
66. Young M & Funder JW 2004 Eplerenone, but not steroid withdrawal, reverses cardiac fibrosis in deoxycorticosterone/salt-treated rats. Endocrinology 145 3153–3157. (doi:10.1210/en.2004-0005)
67. Young MJ & Rickard AJ 2012 Mechanisms of mineralocorticoid saltinduced hypertension and cardiac fibrosis. Molecular and Cellular Endocrinology 350 248–255. (doi:10.1016/j.mce.2011.09.008)
68. Zannad F, McMurray JJV, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ & Pitt B 2010 Eplerenone in patients with systolic heart failure and mild symptoms. New England Journal of Medicine 364 11–21. (doi:10.1056/NEJMoa1009492)
69. Ziera T, Irlbacher H, Fromm A, Latouche C, Krug SM, Fromm M, Jaisser F & Borden SA 2009 Cnksr3 is a direct mineralocorticoid receptor target gene and plays a key role in the regulation of the epithelial sodium channel. FASEB Journal 23 3936–3946. (doi:10.1096/fj.09-134759)